Our leadership team has a proven track record of discovering novel compounds that target bacteria that are resistant to available anti-infectives. Our experienced, industry-leading management team has extensive experience in discovering, developing and gaining regulatory approval for anti-infective medications and in working with public-private partnerships focused on new anti-infectives to combat antimicrobial resistance, and has advanced four products to regulatory approval during the last decade.
